The 2026-10-12 announcement reports the first participant enrolled in Phase 3 DAYBreak CLL-306. NX-5948 is an oral, brain-penetrant BTK degrader. The company also reported collaboration progress with Roche, Gilead, Pfizer, and Sanofi.
Completed offering with a verifiable amount identified in this review; registered offering capacity is not treated as actual financing.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
The 2026-10-12 announcement reports the first participant enrolled in Phase 3 DAYBreak CLL-306. NX-5948 is an oral, brain-penetrant BTK degrader. The company also reported collaboration progress with Roche, Gilead, Pfizer, and Sanofi.
Program / service
Target / indication
Representative stage
Evidence & scope
bexobrutideg（NX-5948）
BTK · B-cell malignancies including CLL/SLL; the representative Phase 3 program is in CLL
Phase 3
Human results reported by the source; see facts and original materials for type and quality
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.
A Frontiers in Pharmacology review compares direct MCL-1 inhibition with approaches that reduce its abundance, including transcriptional interventions and targeted degradation. The original abstract highlights limited single-agent activity and cardiac safety concerns with inhibitors, while positioning degradation as an unvalidated clinical strategy. Biomarker-guided combinations and dynamic BH3 profiling are discussed; this review does not report a new clinical trial.
Evommune licensed EVO570, formerly HC118, from Hinova for development and commercialization outside Greater China. Upfront consideration totals $30 million: $20 million cash and $10 million in pre-funded warrants. Additional development, regulatory, and commercial milestones could reach approximately $1.1 billion, plus royalties. Phase 1 was expected to begin shortly; the announcement does not establish human efficacy.
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
